Latigo Biotherapeutics, Inc. (LTGO) Stock Price & Analysis
Latigo Biotherapeutics, Inc. (LTGO) closed at USD 15.83 on Wednesday, October 28, 2026, up 4.08% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 15.21; the Oct 28, 2026 session ranged USD 15.14–16.06 on volume of 187,418 shares. Market capitalization is $1.05B, with a 52-week range of USD 13.5–25.93 (NMS). Source: Nexqual, retrieved October 29, 2026 at 07:36 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LTGO.md
Key facts (LTGO)
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $5.0M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 52.25 (range 36–73).
- Total return with dividends: 1Y -13.3% vs S&P 500 +13.6%; 5Y -13.3% vs S&P 500 +79.8%.
- Next earnings: 2026-11-12, EPS estimate USD -0.67, revenue estimate $0K.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (LTGO)
Earnings yield -9.10% · Net cash $20.0M · EV $1.03B
Insider purchases (SEC Form 4, open-market, last ~7 months) (LTGO)
2 purchases, $5.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-10 | Foresite Capital Management V, Llc | 140,000 | $2.5M | 18 | Too little history (no open-market trades in 2023–2025) | |
| 2026-08-10 | Tananbaum James B. | Director | 140,000 | $2.5M | 18 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (LTGO)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 52.25 (low 36, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-01 | Leerink Partners | Initiated | Outperform | $36 |
| 2026-09-01 | Jefferies | Initiated | Buy | $50 |
| 2026-09-01 | Guggenheim | Initiated | Buy | $50 |
Total return (dividends reinvested) (LTGO)
| 1Y (from 2026-08-07) | 5Y (from 2026-08-03) | |
|---|---|---|
| Total return | -13.3% | -13.3% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | — | — |
| Volatility (annualized) | 75.4% | 77.5% |
| Max drawdown | -44.0% (Aug 2026→Oct 2026) | -42.2% (Aug 2026→Oct 2026) |
LTGO major shareholder filing: Schedule 13D, Aug 17, 2026
Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC, Foresite Capital Fund V, L.P. filed a Schedule 13D with the SEC on Aug 17, 2026, reporting up to 14.50% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock; general market and economic conditions; ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities; and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Source: SEC EDGAR, Schedule 13D filed Aug 17, 2026. Quoted word for word; Nexqual adds no interpretation.
LTGO earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$27.59 | −$0.66 | Miss −4080.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
LTGO recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 3, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Sep 3, 2026 | 8-K | Quarterly results |
| Aug 18, 2026 | Schedule 13G | AI Biotechnology LLC, Access Industries Holdings LLC: 5.0% of shares, passive 5%+ holder |
| Aug 17, 2026 | Schedule 13D | Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC: 14.5% of shares, 5%+ holder that may seek to influence the company “The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the Common Stock…” |
| Aug 17, 2026 | Schedule 13G | RA Capital Management, L.P., Peter Kolchinsky: 8.4% of shares, passive 5%+ holder |
| Aug 13, 2026 | Schedule 13G | Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd.: 7.0% of shares, passive 5%+ holder |
| Aug 10, 2026 | 8-K | Bylaws or fiscal-year change; Other material event “On August 10, 2026, the Company completed its IPO of an aggregate of 19,200,000 shares of common stock at a price to the public of $18.00 per share. The aggregate gross proceeds from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $345.6 million.” |
| Aug 4, 2026 | S-1/A | Registration of new shares |
| Aug 3, 2026 | S-1/A | Registration of new shares |
| Jul 17, 2026 | S-1 | Registration of new shares |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
LTGO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.67 | $0.00 | −$0.67 | $0 | 2 |
| Next quarter (ends Dec 2026) | $-0.85 | $0.00 | −$0.85 | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-3.01 | $0.00 | −$3.01 | $0 | 3 |
| Next fiscal year (ends Dec 2027) | $-2.32 | $0.00 | −$2.32 | $0 | 4 |
Key Statistics (as of October 29, 2026 at 07:36 UTC)
| Price | USD 15.83 |
|---|---|
| Change | ▲ 4.08% (up) |
| Previous Close | USD 15.21 |
| Open | USD 15.27 |
| Day Range | USD 15.14 – 16.06 |
| 52-Week Range | USD 13.5 – 25.93 |
| Volume | 187,418 shares |
| Market Cap | $1.05B |
| Exchange | NMS |
Technical Analysis (LTGO)
Nexqual's technical model rates LTGO "SELL" based on 1 bullish and 4 bearish signals across 58 daily candles, as of October 29, 2026 at 07:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.78 (neutral) |
| vs SMA50 | Below (USD 19.18) |
| MACD | -0.92 (negative) |
Analyst Ratings (LTGO)
Wall Street analysts rate LTGO "Buy" based on 4 analysts, with a mean price target of USD 52.25 (range USD 36–73), per Nexqual as of October 29, 2026 at 07:36 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 52.25 |
| High Target | USD 73 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (LTGO)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -27.59 vs est -0.67 ▼ miss |
Source: Nexqual, October 29, 2026 at 07:36 UTC.
Financials & Fundamentals (LTGO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 2.5 |
| Current Ratio | 1.15 |
| Total Cash | $55.00M |
| Total Debt | $31.25M |
Source: Nexqual, October 29, 2026 at 07:36 UTC.
Financial Health Score (LTGO)
Nexqual rates Latigo Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:36 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $55M cash and investments vs $35M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$103M (TTM) |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -147.5% (last 4 quarters, SEC) |
Ownership (LTGO)
| Insider Ownership | +4.98% |
|---|---|
| Institutional Ownership | +80.73% |
| Shares Outstanding | 66.30M |
| Float | 21.74M |
Source: Nexqual, October 29, 2026 at 07:36 UTC.
Leadership (LTGO)
Latigo Biotherapeutics, Inc. is led by Nima Farzan, CEO, President & Director, per Nexqual as of October 29, 2026 at 07:36 UTC.
| CEO, President & Director | Nima Farzan |
|---|---|
| Chief Business Officer & CFO | Neha Krishnamohan |
| Senior Vice President of Operations | Julia Chapman |
| Vice President of Corporate Development | Caroline Dougherty |
| Senior Vice President of Discovery | Bryan Moyer |
Major Backers & Investors (LTGO)
Notable institutional backers of Latigo Biotherapeutics, Inc. include Fidelity, Variable Insurance Products Fund II-VIP Contrafund Portfolio, according to Nexqual as of October 29, 2026 at 07:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 3.4% |
| Variable Insurance Products Fund II-VIP Contrafund Portfolio | 0.14% |
Source: Nexqual, October 29, 2026 at 07:36 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 91.97 | ▼ 0.23% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| PRAX | Praxis Precision Medicines, Inc | USD 285.48 | ▲ 6.69% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:36 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt